Try our beta test site
116 studies found for:    Adcetris
Show Display Options
Rank Status Study
1 Not yet recruiting Trial of Adcetris in CD30+ Malignant Mesothelioma
Conditions: Lung Diseases Due to External Agents;   Mesothelioma
Intervention: Drug: Brentuximab Vedotin
2 Recruiting Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas
Condition: Relapsed or Refractory EBV-and CD30-positive Lymphomas
Intervention: Drug: brentuximab vedotin
3 Recruiting Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient
Conditions: Clinical Efficacy;   Safety
Intervention: Drug: Adcetris-Levact
4 Active, not recruiting A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity
Condition: Hodgkin Disease
Intervention: Drug: Brentuximab Vedotin
5 Recruiting Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"
Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma
Intervention: Drug: Brentuximab vedotin (recombinant)
6 Completed A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Condition: Primary Mediastinal Large B-cell Lymphoma.
Intervention: Drug: Brentuximab Vedotin
7 Active, not recruiting Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Condition: Germ Cell Cancer
Intervention: Drug: Brentuximab Vedotin
8 Not yet recruiting To Assess the Efficacy of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma
Condition: Non-Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
9 Active, not recruiting A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Brentuximab vedotin
10 Completed
Has Results
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
Conditions: Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell
Interventions: Drug: brentuximab vedotin;   Drug: rituximab
11 Active, not recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: Brentuximab vedotin
12 Active, not recruiting Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation
Conditions: Leukemia, Acute Myeloid;   Leukemia, Lymphoblastic,Acute;   Myelodysplastic Syndromes
Intervention: Drug: brentuximab vedotin
13 Active, not recruiting Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Condition: Hodgkin's Lymphoma
Intervention: Drug: TGR-1202 + brentuximab vedotin
14 Recruiting Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL
Condition: ALK+ Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab vedotin;   Drug: Imatinib
15 Terminated Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)
Conditions: Graft-vs-Host Disease;   GVHD
Intervention: Drug: Brentuximab Vedotin
16 Active, not recruiting Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: brentuximab vedotin;   Drug: bendamustine
17 Active, not recruiting Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Condition: Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
18 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin
19 Withdrawn Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly
Condition: Lymphoma
Intervention: Drug: brentuximab vedotin
20 Not yet recruiting A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
Condition: Hodgkin Disease
Interventions: Drug: Brentuximab vedotin;   Drug: Doxorubicin;   Drug: Vinblastine;   Drug: Dacarbazine

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.